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Themajor gene for Hirschsprung disease (HSCR) encodes the receptor tyrosine kinase RET. In a study of 690 European- and 192 Chinese-
descent probands and their parents or controls, we demonstrate the ubiquity of a >4-fold susceptibility from a C/T allele (rs2435357:
p ¼ 3.9 3 1043 in European ancestry; p ¼ 1.1 3 1021 in Chinese samples) that probably arose once within the intronic RET enhancer
MCSþ9.7. With in vitro assays, we now show that the T variant disrupts a SOX10 binding site within MCSþ9.7 that compromises RET
transactivation. The T allele, with a control frequency of 20%–30%/47% and case frequency of 54%–62%/88% in European/Chinese-
ancestry individuals, is involved in all forms of HSCR. It is marginally associated with proband gender (p ¼ 0.13) and signiﬁcantly so
with length of aganglionosis (p ¼ 7.6 3 105) and familiality (p ¼ 6.2 3 104). The enhancer variant is more frequent in the common
forms of male, short-segment, and simplex families whereasmultiple, rare, codingmutations are the norm in the less common andmore
severe forms of female, long-segment, and multiplex families. The T variant also increases penetrance in patients with rare RET coding
mutations. Thus, both rare and commonmutations, individually and together, make contributions to the risk of HSCR. The distribution
of RET variants in diverse HSCR patients suggests a ‘‘cellular-recessive’’ genetic model where both RET alleles’ function is compromised.
The RET allelic series, and its genotype-phenotype correlations, shows that success in variant identiﬁcation in complex disorders may
strongly depend on which patients are studied.Introduction
The hallmark of Mendelian disease is that the underlying
mutations have the same, recognizable inheritance pattern
and effect (loss or gain of function) across families, indepen-
dent of genetic background. Different families often have
different molecular mutations: allelic diversity is high and
usually maintained by mutation-selection balance of indi-
vidually rare mutations. In human families segregating
such a disease, the recurrence risks to relatives depend
only on the degree of relationship to the proband, and triv-
iallyon the frequencyof themutantallele in thepopulation,
thus making genetic counseling simple and pragmatic. At
the other extreme, numerous, if not most, human diseases
have complex, multifactorial inheritance where the causa-
tion arises from the small allelic differences at many genes
in an equal and additive manner.1 Complex disorders are
now thought to involve signiﬁcant unequal and nonaddi-
tive genetic effects as well. For these phenotypes, recurrence
risk is not a property of any single gene but rather an emer-
gent property of the ensemble genotypes at many loci.1Center for Complex Disease Genomics, McKusick-Nathans Institute of Genet
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unique genetic features of multifactorial diseases (traits)
that distinguish them from Mendelian ones.2 First, the
underlying disease allele is polymorphic. Second, recur-
rence risks in relatives of a proband depend inversely on
population incidence, increasing with greater severity and
being greater for a less frequently affected class. Finally,
recurrence risks vary across families, even for the same
genetic relationship. Thus, genetic counseling is much
more complex and dependent on the degree of familial
aggregation.3,4 Carter explained these ‘‘non-Mendelian’’
features by using the additive multifactorial model of
genetic effects that produces a normal distribution of
liability (genotype and exposure) in thepopulation, adistri-
bution that shifts higher along the liability scale in relatives
of a proband, with affected individuals having liability
beyond a threshold.2 Although the multifactorial model is
well established, its molecular properties remain unclear,
speciﬁcally how the ensemble of multilocus genotypes
lead to the corresponding non-Mendelian phenotypic
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variant’’ and the ‘‘common disease-rare variant’’ hypoth-
eses may be true for speciﬁc mutant alleles but need not
be general rules for all complex disease genes and their
alleles.5,6 To explore how the actual allelic diversity of
a gene impacts the phenotypic diversity and non-Mende-
lian features of a complex disease, we examined the muta-
tional diversity and phenotypic consequences of the RET
(MIM 164761) tyrosine kinase in Hirschsprung disease
(HSCR [MIM 142623]). We demonstrate that both rare
and common mutations, coding and noncoding, within
the same gene contribute to HSCR in unique and speciﬁc
ways that lead to recognizable genotype-phenotype associ-
ations.Consequently, for a complexdisease, thepatientswe
choose to study canuncover either rare or commonvariants
and may be one major reason for recent debates on the
frequency of mutant alleles and their genetic effects, and
the success or failure of replication of genetic ﬁndings.
Hirschsprung disease (HSCR), or congenital intestinal
aganglionosis, is a developmental defect associated with
the lack of intramural ganglion cells in the myenteric
and submucosal plexuses along varying segments of the
gastrointestinal tract: it is classiﬁed into short-segment
(S-HSCR; aganglionosis up to the upper sigmoid colon),
long-segment (L-HSCR; aganglionosis up to the splenic
ﬂexure and beyond), and total colonic aganglionosis
(TCA) forms. The disorder shows marked differences in
incidence with rates of 15 and 28 cases per 100,000 live
births among Europeans and Asians, respectively.3 HSCR
has all the hallmarks of a classical multifactorial disorder
displaying high heritability (81%–100% depending on
the sex of the proband and affected sibling), large sex
difference (sex ratio 3.9), high sibling recurrence risk
(200-fold greater than the population), and non-Mende-
lian inheritance in families.4 Indeed, HSCR was one of
Carter’s seminal examples of multifactorial inheritance.7
Positional cloning and candidate gene analysis in syn-
dromic and familial cases have identiﬁed 11 genes (RET,
GDNF [MIM 600837], NRTN [MIM 602018], SOX10 [MIM
602229], EDNRB [MIM 131244], EDN3 [MIM 131242],
ECE1 [MIM 600423], ZFHX1B [MIM 605802], PHOX2B
[MIM 603851], TCF4 [MIM 602272], and KIAA1279
[MIM 609367]) withmutations in HSCR; of these, the tyro-
sine kinase RET is the major gene with >80% of all known
mutations.3,8 Coding or splice junction mutations at these
genes have between 50% and 70% penetrance, show sex
dependence, and are rare (<1%) in the population. These
mutations have been identiﬁed in ~50% of familial (mostly
L-HSCR, TCA) and up to 20% of sporadic (mostly S-HSCR)
cases and cumulatively explain ~0.1% of the heritability.
Consequently, although the identiﬁed genes have led to
a deep understanding of the genetic basis of HSCR and
are important to speciﬁc families, they are not a signiﬁcant
explanation of its incidence. In contrast, a common (24%
frequency in Europeans) RET susceptibility allele within an
enhancer in intron 1 impacts all forms of HSCR and
explains ~2% (1.14% in females, 2.63% in males) of the
heritability or 20-fold greater than the contribution byThrare coding variants.9 The vast majority (80%) of HSCR
occurs as S-HSCR with multifactorial inheritance, a recur-
rence risk of 4%, and a sex ratio of 5.5.4 Thus, the typical
HSCR case is isolated (nonsyndromic and negative family
history) and the fewmultiplex families observed are largely
comprised of affected siblings. Genome-wide linkage
studies have identiﬁed three loci (RET and two yet uniden-
tiﬁed genes at 3p12 and 19q21) that are together necessary
and sufﬁcient to explain the segregation and recurrence
risk of S-HSCR.10 Other modiﬁer genes have also been
mapped.8 However, RET is the only gene known to play
amajor role in all forms of HSCR susceptibility, and a quan-
titative and unbiased study of its allelic spectrum provides
clues on the role of both rare and common sequence vari-
ants in the complex inheritance of HSCR, particularly its
relationships to disease subtypes that are correlated with
risk, namely, gender, segment length, and familiality.
We studied 882 probands and their 1478 ﬁrst-degree
relatives from US, European, and Chinese families to
examine the role of RET genetic variation with respect to
HSCR and its subtypes and performed two types of molec-
ular analyses: sequencing of the protein coding sequence
(CDS) and haplotype analysis of single nucleotide poly-
morphisms (SNPs) across the entire 61.8 kilobase (kb)
RET locus.We unequivocally demonstrate the signiﬁcantly
different genetic properties of rare versus common vari-
ants, their complementary effects on disease severity and
prevalence, and the sensitivity of recurrence risk to corre-
lated risk factors. Our conclusions have signiﬁcant implica-
tions for disease gene versus disease variant/mutation
discovery and interpretations of the genetic architecture
of complex traits.Material and Methods
Patient Collection and DNA Samples
Each center ascertained patients and their families under informed
consent and with ethical guidelines of their respective home insti-
tutions. HSCR probands were identiﬁed either from a survey of
surgical/clinical records from hospitals or large physician practices
or from referrals to each center by their physicians, genetic
counselors, or family members: therefore, there is the likelihood
of biased representation of speciﬁc disease subtypes at each
center. The phenotypic diagnosis of HSCR and the segment length
involved was based on surgery, pathology, or other medical
records, with affected individuals being classiﬁed as total colonic
aganglionosis (TCA), long-segment (L-HSCR; aganglionosis of
the splenic ﬂexure and beyond), or short-segment (S-HSCR; agan-
glionosis distal to the splenic ﬂexure and usually involving the
sigmoid colon) HSCR. A random collection of HSCR patients,
without regard to segment length, gender, or familiality, with
or without other associated anomalies, and with or without
demonstrated coding sequence RET mutations, were studied.
Each investigator provided DNA samples and phenotypic data
from probands and their families for central genetic and statistical
analysis at Johns Hopkins University except that the Chinese case-
control samples were genotyped in Hong Kong. In total, 586
father-mother-proband trios (133 from France, 127 from Spain,e American Journal of Human Genetics 87, 60–74, July 9, 2010 61
Figure 1. Genetic Associations between
RET and HSCR in Two Populations
Transmission disequilibrium test (TDT) of
polymorphisms across the RET locus.
-logP values for each of 14 SNPs, with
purple triangles representing genotypes
from individuals of European descent
(Italy, France, Netherlands, Spain, and
US) and green circles those of Chinese
descent (trio and case-control p values
were combined via Fisher’s method), are
shown on the y axis against the physical
locations of SNPs with respect to RET
exons (orange). The circled SNP
rs2435357 segregates a functional hypo-
morphic enhancer mutation; rs3026785
is monomorphic in the Chinese.120 from USA, 125 from Netherlands, 81 from Italy) and 104
parent-proband duos (27 from France, 14 from Spain, 47 from
USA, 4 from Netherlands, 12 from Italy) of European descent
were genotyped; 94 parent-child samples (49 trios and 45 duos)
together with 98 cases and 168 controls from Hong Kong were
also examined. The distribution of gender, familiality, and
segment length for the complete set of 882 probands is provided
in Table S1 available online.
SNP Genotyping
A total of 2672 samples were genotyped but after sample and data
cleaning, 882 probands together with 1260 of their parents (24
affected), 218 siblings (65 affected sibs), and 64 other relatives
(22 affected), for a total of 2424 samples, were analyzed (Table S2).
The DNA samples were shipped as lyophilized genomic DNA
and were resuspended in water prior to genotyping. All liquid
handling steps were completed on a Tecan Genesis Workstation.
Each of 14 SNPs (Table S3) was genotyped with Taqman tech-
nology (Applied Biosystems, Foster City, CA). The SNPs were
chosen to physically span the entire locus (Figure 1; Table S3) so
that copy number mutations could be detected, to span the two
major LD blocks at RET so that the genetic association signal could
be detected anywhere within the gene and based on our prior
knowledge of SNP assay performance. In brief, genotyping reac-
tions were cycled on MJ tetrads and endpoint reads performed
on the ABI Prism 7900HT with the SDS2.2 software for allelic
discrimination. Genotypes were called only when samples were
within a clearly identiﬁed cluster. One hundred and twenty
clinical samples and four CEPH families were genotyped in dupli-
cate: from a single discordant call among 3114 replicate geno-
types, we estimated our error rate to be 0.032%. Information on
the genotyping performance of the SNPs studied in the trios is
shown in Table S3. Genotyping in ‘‘clinical’’ or nonreference
samples can expose several different types of ‘‘errors:’’ sample
misidentiﬁcation (laboratory errors or disputed parentage), DNA
degradation, genotyping errors, and copy number variants and
mutations. All of these families have been used in previous
HSCR genome-wide linkage analyses, making disputed paternity
very unlikely; furthermore, no trio demonstrated apparent
parental exclusions at multiple markers except for nine families
that probably harbor de novo deletion mutations (see main62 The American Journal of Human Genetics 87, 60–74, July 9, 2010text). This inference was based on ﬁnding SNPs with genotypes
in parents well within clusters but with offspring genotypes
as apparent homozygotes and/or outside clusters; the claims
were buttressed with the ﬁnding of multiple SNPs showing
Mendelian inconsistencies or being consistent with deletion
from a single parental origin. To address DNA sample quality
issues, we observed that missing genotypes were nonrandomly
distributed across samples: ~30% of samples had any missing
data, the majority (62%) of which had only one missing genotype
and 97% of which had six or fewer missing genotypes; we chose to
eliminate from analysis the ~3% of samples that showed seven or
more missing genotypes (Figure S1). Genotyping errors remain
a small possibility in these data; to reduce this impact, we elimi-
nated all Mendelian inconsistencies to observe a genotyping call
rate of more than 95% with the exception of rs1864410. To assess
genotype quality, we tested the Hardy-Weinberg equilibrium on
all parents of trios; as shown in Table S3, none of the SNPs were
statistically signiﬁcant given multiple corrections (14 tests: p <
0.0036). The 98 cases and 168 controls fromHong Kong were gen-
otyped with a multiplexed assay with Sequenom (San Diego, CA)
technology; all SNPs, except rs3026785, were polymorphic and
clustered well.
DNA Sequencing
DNA sequencing to reveal coding sequence (CDS) mutations in
the 20 RET exons was performed by PCR ampliﬁcation followed
by automated DNA sequencing on an ABI 3100 or 3730XL; the
Netherlands samples were prescreened by SSCP (single strand
conformational polymorphism) and DGGE (density gradient
gel electrophoresis) while the Italian samples were prescreened
by DHPLC (denaturing high performance liquid chromatography)
prior to DNA sequencing. For this study, we distinguished disease-
causing mutations from neutral variation if the alteration was
absent from 200 control chromosomes from the respective local
population and (1) introduced a premature stop codon, (2) altered
a conserved splice junction, or (3) was statistically predicted to be
deleterious or had been previously demonstrated to affect RET
protein function.11 We identiﬁed a total of 75 unique (10 non-
sense or frame shift, 48 missense, and 15 splice junction, 2 non-
coding) mutations in 85 families (16 French, 9 Spanish, 20 Dutch,
17 Italian, 17 Chinese, 6 US families).
Association Data Analysis
From the genotypes of trios, and separately for the Chinese case-
control samples, haplotypes were estimated with PHASE v2.112
and classiﬁed as being transmitted (Tr) or untransmitted (Un)
to HSCR offspring. Allele frequencies were estimated separately
for Tr and Un chromosomes by gene counting and tests of
Hardy-Weinberg performed by a standard c2 test with one degree
of freedom (df) based on the four classes AA, AB, BA, and BB
for alleles A and B on Tr and Un chromosomes, respectively.
This tactic was necessary because there was prior knowledge of
association between RET SNPs and HSCR and failure to account
for this known allelic difference on Tr/Un chromosomes would
falsely inﬂate the c2 statistic. Population recombination rates
were estimated for Tr and Un chromosomes separately with
complete trios and the simple hot spot model implemented in
PHASE v2.1. Estimates of linkage disequilibrium (LD) on Tr and
Un chromosomes were calculated and visualized with GOLD13
(Figure S2). All association tests between RET genotypes and
HSCR subtypes were performed with standard contingency c2
tests with 1 or 2 df, as appropriate. The transmission disequilib-
rium test14 (TDT) was performed on parent-child trio genotypes
via a maximum likelihood method9 that also estimated the trans-
mission (segregation) ratio t. Estimation of disease penetrance by
RET rs2435357 genotype was performed as previously described9
by using the inverse Bayes’ rule on genotypes of probands with
an estimated HSCR incidence of and a rs2435357 background T
allele frequency of 15 cases per 100,000 live births and 24%, and
28 cases per 100,000 live births and 47%, for those with European
and Chinese descent, respectively.
Under the null hypothesis of no LD, the TDT has a c2 distribu-
tion with one degree of freedom (df). Under the alternative LD
hypothesis, the value of the statistic can be used to quantify
some properties of the genetic locus contributing to the complex
disease; for a sample of n transmissions, the expected value of
the test statistic is n(2t  1),2 where t is the transmission
frequency; under random association, t ¼ 1/2. Thus, t can be esti-
mated from parent-offspring trio genotype data.
Assume a complex disease autosomal locus with genotypes DD,
Dd, and dd, population frequencies p2, 2pq, and q2, and marginal
penetrance values of f0, f1, and f2, respectively; assume that d is
the mutant allele and D the wild-type. Assuming contributions
from other genes and environmental factors, the penetrance
values are neither zero nor unity and ordered as f2 R f1 R f0.
The marginal penetrance of the alleles D and d are then fD ¼
pf0 þ qf1 and fd ¼ pf1 þ qf2 with total disease incidence f ¼ pfD þ
qfd. Consequently, under single ascertainment of probands, the
transmission ratio is:
t ¼ fd=

fD þ fd

¼ g=ð1þ gÞ,
where g is the penetrance (risk) ratio fd/ fDR 1. The precise inter-
pretation of g depends on whether allelic action at the locus is
additive or multiplicative; in the simple multiplicative risk model,
g is also the allelic risk ratio but under an additive model it is an
allele frequency-weighted sum of individual penetrance values.
Note also that g and t can be estimated from the penetrances f0,
f1, and f2 by assuming a speciﬁc incidence (f) and allele frequency
q only. In contrast, for case-control data, the frequency of the
susceptibility allele among cases (q’) is related to the risk ratio as
g ¼ q’p/qp’ where p’ ¼ 1  q’. We interpret g as the penetrance
risk ratio or the relative allelic (genetic) effect.ThEstimating Haplotype Frequencies of Rare and
Common RET Mutations
We denote the collection of all coding and enhancer mutations by
m and e, respectively, with the wild-type states being denoted asþ.
Consequently, four ‘‘haplotypes’’ can be distinguished þþ, eþ,
þm, and em with frequencies y1, y2, y3, and y4, respectively.
Thus, individuals who can have either of the four features of
harboring no mutations (00), enhancer variant only (10), CDS
variant only (01), and both variants (11) have frequencies
(denoted by f):
f00 ¼ y21,
f10 ¼

y1 þ y2
2y21,
f01 ¼

y1 þ y3
2y21,
f11 ¼ 1 f00  f10  f01:
Because the frequencies of the four classes 00, 10, 01, and 11 are
observed, the maximum likelihood estimates of the haplotype
frequencies are:
y1 ¼
ﬃﬃﬃﬃﬃﬃ
f00
p
,
y2 ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
f00 þ f10
q 
ﬃﬃﬃﬃﬃﬃ
f00
p
,
y3 ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
f00 þ f01
q 
ﬃﬃﬃﬃﬃﬃ
f00
p
,
y4 ¼ 1 y00  y10  y01:
Enhancer Function Analysis
Luciferase Assays
PatientDNAs genotyped as homozygous for themutant rs2435357
(T) and wild-type (C) alleles were ampliﬁed, sequenced to verify
their composition, and cloned into the Gateway pDONR221 entry
vector in accordance with the manufacturer’s protocol (Promega,
Madison, WI). Subsequently, RETMCS sequences were subcloned
into a SmaI site in a Gateway modiﬁed pGL3 (Promega, Madison,
WI) ﬁreﬂy luciferase vector containing an SV40 promoter and
a complete ﬁreﬂy luciferase open reading frame. These constructs
were designated pDSma_RET_MCSþ9.7 (mut and WT) and
pDSma_RET_MCSþ5.1/þ9.7 (mut and WT). Control plasmids
(Promega, Madison, WI) containing only the SV40 promoter and
luciferase open reading frame (pDSma_promoter), or including
an SV40 control enhancer with the above promoter and luciferase
open reading frame (pDSma_control), served as experimental
controls. Expression values were normalized against promoter
only construct (pDSMA_promoter) expression.
The neuroblastoma cell line (Neuro-2a, ATCC# CCL-131) and
the epithelial adenocarcinoma cell line (HeLa, ATCC# CCL-2)
were cultured according to ATCC protocols (ATCC, Manassas,
VA). Approximately 106 cells were cotransfected (Lipofectamine
Plus, Invitrogen, Carlsbad, CA) with 0.4 mg of the appropriate
pDSma ﬁreﬂy luciferase plasmid and 0.01 mg phRL-SV40 control
Renilla luciferase plasmid. Dual Luciferase Assays (Promega, Mad-
ison, WI) were performed in accordance with the manufacturer’s
instructions. Luciferase activity was assayed 24 hr after transfec-
tion (Monolight 2010, Analytical Luminescence Laboratories,e American Journal of Human Genetics 87, 60–74, July 9, 2010 63
CA) in triplicate and were consistent upon repetition. Statistical
signiﬁcance was determined with a two-tailed t test assuming
unequal variances.
cDNA Transactivation Assays
pCMV_Sox10 (gift of W. Pavan, NHGRI) cDNA was cotransfected
with pDMA_MCSþ9.7. A total of 1 mg of cDNA was transfected
per well in a 24-well plate. Cells were harvested 48 hr after trans-
fection. Transfections and luciferase assays were conducted as
described above. Deletion constructs were generated with the
Stratagene QuikChange II Site-Directed Mutagenesis Kit according
to manufacturer’s protocol.
Chromatin Immunoprecipitation Assays
A modiﬁed protocol based on the EZ ChIP Chromatin Immuno-
precipitation kit (Upstate; #17-371) was followed. N2A cells were
transfected with HA-tagged Sox10 cDNA as described above. Cells
were harvested and formaldehyde cross-linked 24 hr after transfec-
tion. Kit instructions and reagents were utilized for cell lysis,
DNA sonication, immunoprecitation with the HA antibody,
elution of protein/DNA complexes, cross-link reversal, and DNA
puriﬁcation. 2 ml of puriﬁed DNA was added to triplicate real-
time quantitative PCR reactions performed on an ABI 7900
(Applied Biosystems, Foster City, CA) with SYBR-Green reagents
according to the EZ-ChIP protocol. Negative controls included
cells that were not transfected with the HA-tagged cDNA (no trans-
fection), a sample where no antibody was added to immunopre-
cipitate the protein-DNA complex (no antibody), and a sample
where water was the input (mock).Results
A Polymorphic Enhancer Variant at rs2435357
Is Associated with HSCR in the European
and Chinese Populations
Wehave previously demonstrated, in a small sample of 126
parent-child US HSCR trios with differing segment lengths,
that a common polymorphism rs2435357 (previously
termed RETþ3:C/T, with ancestral allele C and derived
mutation allele T) in a noncoding enhancer element
(MCSþ9.7: Multispecies Conserved Sequence located
9.7 kb from the ATG) in intron 1 of RET is a HSCR suscep-
tibility allele.9,15 The genotypes of control individuals
from multiple populations across the world (Human
Genome Diversity Panel) showed that the rs2435357
minor allele had an average frequency of 24% in individ-
uals with European ancestry and 45% in individuals with
Asian ancestry, but was virtually absent (<1%) in Africa.9
Although speciﬁc RET SNP associations with HSCR has
been shown in selected European16,17 and Chinese18
samples, we conducted comprehensive mapping across
the entire RET locus in affected individuals from Europe
and China to identify signiﬁcant genetic effects via
a common set of SNPs.
We examined 14 SNPs, including the enhancer polymor-
phism rs2435357, spanning the 61.8 kb of RET to extract
information on common variation in 519 European
parent-child trios. The SNPs selected, their locations,
genetic properties, and genotyping quality control statis-
tics, together with the samples genotyped, are provided in64 The American Journal of Human Genetics 87, 60–74, July 9, 2010Tables S1–S3 and Figure S1. As shown in Figure 1, there is
highly signiﬁcant evidence of association of HSCR (as
a combined category) via the transmission disequilibrium
test (TDT14) with all 14 RET SNPs. The peak associations
are at rs2435357 (p¼ 3.93 1043) and its intron 1 neighbor
rs2435362 (p ¼ 1.5 3 1043) with which it shows high
linkage disequilibrium (LD: r2 ¼ 0.94 on US and European
untransmitted chromosomes). We also performed a TDT
analysis on 94 trios and duos sampled in Hong Kong: we
obtained an identical pattern of peak signiﬁcant associa-
tions at rs2435357 (p ¼ 3.9 3 105) and rs2435362 (p ¼
2.4 3 106) (Figure 1). In addition, we also examined
rs2435357 in 98 HSCR cases and 168 controls from Hong
Kong: the T allele had a frequency of 0.43 (137/322) in
controls and 0.83 (156/188) in cases (p ¼ 5.1 3 1019).
The combined p value for TDT and case-control for these
Chinese samples is lowest at 1.13 1021 at rs2435357, con-
ﬁrming the replication of the association from TDT anal-
ysis. Overall, the T allele at rs2435357 is common among
HSCR patients in the USA (49% versus 26% in controls),
in Europe (54%–62% versus 20%–30% in controls), and in
Hong Kong (88% versus 47% in controls) (Table S4).
The Enhancer Variant at rs2435357 Disrupts SOX10
Binding and RET trans-Activation In Vitro
Our previous functional analysis demonstrated that
MCSþ9.7 is a gut transcriptional enhancer that shows
reduced activity with the T allele;9 we show here that
this reduced activity is due to a reduced ability of SOX10
to bind to MCSþ9.7 and transactivate RET in T-bearing
rather than C-bearing alleles. SOX10 has previously
been demonstrated to directly activate RET transcription
through interaction with PAX3 at the RET promoter.19,20
We have here identiﬁed two putative SOX10 transcription
factor binding sites (TFBS) within MCSþ9.7 (Figure 2A).
The SOX10 core binding sequence, 50A/TA/TCAAT/A30,
has been identiﬁed and functionally veriﬁed within pro-
moters of several SOX10-responsive genes, including
RET.19 In wild-type RET MCSþ9.7, the more 50 putative
SOX10 TFBS (SOX10-BS1) exactly matches the core bind-
ing sequence21–24 and lies 58 nucleotides 50 to rs2435357.
SOX10-BS1 is conserved only in primates as seen in
sequence alignments (Figure 2A). The second putative
TFBS (SOX10-BS2) encompasses rs2435357. The putative
site, 50TACAC/TGG30 (bolded C is the ancestral allele), is
not an exact match to the consensus binding site; how-
ever, a similar sequence (50TACACAG30) in the promoter
of the myelin protein zero (MPZ) gene has been shown
to bind SOX10.25,26 The human sequence of SOX10-BS2
is conserved in the primates and pig; cow and carnivore
sequences exactly match the MPZ SOX10 TFBS, and rat
and mouse sequences are closely conserved (Figure 2A).
To determine whether SOX10 could modulate MCSþ9.7
activity, we undertook a series of transactivation assays in
HeLa cells; MCSþ9.7 does not function as an enhancer
in this epithelial cell line and it does not express
SOX10.15 HeLa cells were cotransfected with a construct
Figure 2. SOX10 Transactivation and Binding to MCSþ9.7
(A) Location and conservation of putative SOX10 transcription factor binding sites (TFBS). Human genomic sequence is aligned with the
orthologous sequence interval in eight different mammals via multi-PIPmaker. The putative SOX10 TFBS (SOX10-BS1 and SOX10-BS2)
are highlighted in orange. The HSCR-associated variant rs2435357 is boxed in black.
(B) Reporter expression in HeLa cells of MCSþ9.7 when cotransfected with SOX10 cDNA. Mutant (mut) and wild-type (WT) correspond
to nucleotides T and C, respectively. Expression difference between mut and WT constructs is signiﬁcant p < 0.01 by the two-tailed
unpaired t test as indicated by the asterisk; error bars report standard errors of triplicate quantitative PCR reactions here and in (C)–(E).
(C and D) Deletion of MCSþ9.7 putative SOX10 binding sites reduces luciferase reporter expression in vitro. Expression in HeLa cells of
altered MCSþ9.7 luciferase reporter constructs when cotransfected with SOX10. MCSþ9.7DBS1 and MCSþ9.7DBS2 correspond to the
deletions of the two putative SOX10 TFBS delineated in (A). Luciferase expression values for MCSþ9.7DBS1 are shown in (C). Luciferase
expression values for MCSþ9.7DBS2 are shown in (D).
(E) SOX10 physically associates with MCSþ9.7 as demonstrated by chromatin immunoprecipitation. x axis is fold enrichment normal-
ized to the no antibody control. Also included are a negative transfection control and a mock (no sample) control.expressing SOX10 under the control of the CMV pro-
moter (pCMV_Sox10) and the luciferase reporter vector
pDSMA_MCSþ9.7, containing MCSþ9.7 in context of
the SV40 minimal promoter. Cotransfection with pDSMA_
MCSþ9.7 and pCMV_Sox10 signiﬁcantly increased
luciferase expression from the pDSMA_MCSþ9.7 vector
(Figure 2B) and suggests a role for SOX10 in RET transcrip-
tional modulation through MCSþ9.7.ThTo evaluate the potential pathological signiﬁcance of
rs2435357T, we cotransfected pCMV_Sox10 with both
50-TACATGG-30 and 50-TACACGG-30 allele-bearing forms
in pDSMA_MCSþ9.7. Transfection with MCSþ9.7 con-
taining the T allele results in a statistically signiﬁcant, but
small, decrease of SOX10-dependent luciferase expression
(Figure 2B). The magnitude of this effect is not entirely
unexpected given the hypomorphic nature of the mutante American Journal of Human Genetics 87, 60–74, July 9, 2010 65
Table 1. Single Ancestral Origin of the rs2435357 RET Enhancer Variant
European Chinese
Haplotype Tr (%) Un (%) Tr (%) Un (%) Cases (%) Controls (%)
T G A A A T A G A C A T G T 28.2 10.2 7.2 3.1 5.1 3.3
T G A A A T A G A C G G C T 24.8 11.4 77.3 42.7 70.4 36.0
T G C A C C A A G C G G G C 1.4 4.7 0 0 0.5 0.0
T G C A C C G A G C A T G T 1.4 4.5 3.1 8.3 2.0 6.5
T G C A C C A A G G A T G T 3.8 6.9 0 0 0.0 0.6
C G C A C C A A G G A T G T 8.2 18.4 1 7.3 2.0 6.3
C G C A C C A A G G G G C T 1 1.8 2.1 4.2 0.0 0.3
C G C A C C A A G C A T G T 4.3 2.6 0 1 0.0 0.3
T C C G C C G A G C A T G T 20.2 31.2 5.2 28.1 11.2 27.7
Other Haplotypes 6.8 8.4 4.1 5.2 9.0 19.0
Haplotypes for 14 SNPs (ordered as in Figure 1 and Table S3) were separately estimated from all available trios of European and Chinese ancestry, as well as from
the Chinese case-control samples. Transmitted (Tr) and untransmitted (Un) haplotypes are shown with rs2435357 (C: wild-type and T: mutant) in bold. The first
two haplotypes show an elevated frequency on Tr versus Un chromosomes and are the only haplotypes known to contain the mutant allele.allele.9 To determine whether either SOX10 TFBS is re-
quired for the transactivation of RET through MCSþ9.7,
we individually deleted and tested each site from
pDSMA_MCSþ9.7. Deletion of a 6 bp core sequence
encompassing SOX10-BS1 did not result in a signiﬁcant
diminution of luciferase activity compared with the
wild-type construct (Figure 2C). By contrast, deletion of
SOX10-BS2 showed a signiﬁcant 4-fold decrease in lucif-
erase activity compared with the wild-type (Figure 2D).
These data are consistent with a critical role for SOX10-
BS2 binding of SOX10 in RET activation via MCSþ9.7
and are thus consistent with its potential role in HSCR
pathogenesis.
Todirectly conﬁrmthat SOX10enhances reporter expres-
sion by physical association with MCSþ9.7, we undertook
chromatin immunoprecipitation (ChIP) analysis in a bio-
logically relevant neuroblastoma cell line (Neuro2A). In
brief, Neuro2A cells were transfected and incubated
with hemagglutinin (HA)-tagged SOX10 cDNA and ChIP
was performed with an antibody to the HA tag; binding to
RETMCSþ9.7 was detected by real-time quantitative PCR.
Our results indicate that binding of HA-tagged SOX10
protein to MCSþ9.7 was enriched compared to the no
antibody control, the no transfection control, and the
mock IP (Figure 2E). These data indicate that SOX10 physi-
cally interacts with MCSþ9.7, consistent with the above
data and a potentially important role played by SOX10 in
RET activation via MCSþ9.7. These data also demonstrate
that rs2435357, and not rs2435362, is the susceptibility
factor.
The Enhancer Mutation at rs2435357 Has a Likely
Single Worldwide Origin
The high frequency of the rs2435357 T allele among
European and Chinese HSCR cases does not distinguish
between the possibilities of a single versus recurrent muta-66 The American Journal of Human Genetics 87, 60–74, July 9, 2010tion for this susceptibility allele. To address this question,
we constructed 14 SNP haplotypes on chromosomes trans-
mitted (Tr) and untransmitted (Un) to probands from the
European and Chinese trio genotypes and the Chinese
case-control samples. These results, shown in Table 1,
demonstrate that in both populations the mutant allele
exist on two identical haplotypes. One disease haplotype
(TGAAATAGACATGT: mutation in bold; allelic differences
underlined) has a frequency of 28.2% on Tr chromosomes
in Europeans but is 5.1%–7.2% in the Chinese, with back-
ground (Un) rates of 10.2% and 3.1%–3.3%, respectively.
We designate this as the ancestral haplotype based on
the higher ATG frequency on Un chromosomes in both
Europeans and Chinese. A second disease haplotype
(TGAAATAGACGGCT) has a similar (24.8%) frequency
in Europeans (Un: 11.4%) but a considerably higher prev-
alence (70.4%–77.3%) in the Chinese (Un: 36.0%–42.7%).
Noting the location of the allelic difference between these
two disease haplotypes at the 30 end (GGC versus ATG),
and their frequency difference, the most parsimonious
hypothesis is that the mutation occurred once on the
TGAAATAGACATGT haplotype and subsequently recom-
bined to create the TGAAATAGACGGCT haplotype.27
This hypothesis is buttressed by our studies of the recom-
bination pattern within RET. We used the haplotype data
to estimate LD (with the normalized statistic D0) for the
US, European, and Chinese samples. The results show
extensive LD across the 61.8 kb locus with generally
greater association on Tr than on Un chromosomes, as
expected, given the younger age of mutant allele-bearing
chromosomes (Figure S2). Moreover, at least in the US
and European samples, there is a sharp decline in LD across
the region demarcated by the intron 5 SNP rs2565205 and
the intron 8 SNP rs3026750; this feature is absent in the
Chinese samples.We estimated the population recombina-
tion rate r (r ¼ 4Ner, where Ne is the effective population
Table 2. Genetic Effect of the RET Enhancer Mutation at rs2435357 by HSCR Subtypes
Transmitted Counts
Feature T* C* t c21 g p Value
Gender
Male 397 69 0.85 230.9 5.8 3.8 3 1052
Female 138 34 0.80 62.9 4.1 2.2 3 1015
Segment length
Short 318 45 0.88 205.3 7.1 1.5 3 1046
Long 82 10 0.89 56.3 8.2 6.2 3 1014
Total colonic aganglionosis 50 23 0.68 10.0 2.2 1.6 3 103
Unknown 85 25 0.77 32.7 3.4 1.1 3 108
Familiality
Simplex 413 63 0.87 257.4 6.6 6.3 3 1058
Multiplex 122 40 0.75 41.5 3.0 1.2 3 1010
All Probands 535 103 0.84 292.5 5.3 1.4 3 1065
Transmission disequilibrium tests of all available trios classified by gender, segment length of aganglionosis, and familiality. The numbers of transmitted C (wild-
type) and T (mutant) alleles from informative parents, the estimated transmission (segregation) ratio (t), the allelic risk ratio (g), and the significance of association
(p value) are provided.size and r the recombination rate in Morgans/10 kb) that is
expected to be 4. As observed in Figure S3, the RET locus is
a recombination cold spot (relative to the genome) but
almost all the recombination that occurs at this locus
does so in the interval between rs2565205 and rs3026750
at 2–3 times the genomic average. This feature can explain
the origin of the new disease haplotype TGAAATAG
ACGGCT by recombination within this hotspot. We
hypothesize that the recombinant disease haplotype
occurred prior to the differentiation of these two popula-
tions based on its high background frequency in both
Europeans and Chinese and it is the putative recombinant
TGAAATAGACGGCT haplotype that has expanded in
Asia.
Although parsimony suggests that the two disease
haplotypes have a common origin, one ancestral and one
recombinant, it is alsopossible that bothdiseasehaplotypes
arose independently in Europe and both migrated to Asia
but TGAAATAGACGGCT rose to a greater frequency than
TGAAATAGACATGT by genetic drift or selection.
Penetrance at rs2435357 Varies with Hirschsprung
Disease Subtypes
The RET disease haplotypes shows an approximately 2-fold
difference on Tr versus Un chromosomes with the higher
background (Un) frequency leading to a 2-fold higher inci-
dence on the T chromosomes in the Chinese as compared
to the US/European samples, and a concomitant 2-fold
increase in HSCR disease incidence (28 and 15 cases per
100,000 live births, respectively). The lower frequency of
rs2435357T in Africa also predicts the lower disease inci-
dence in Africans.9 Thus, irrespective of the contributions
of other genes to HSCR, the rs2435357 susceptibility alleleThfrequency difference is one explanation of the disease
prevalence difference across populations.
We next tested whether the genetic susceptibility at
rs243537 is similar across three features known to be
associated with overall HSCR risk, namely, gender, familial-
ity (simplex versus multiplex), and segment length varia-
tion (S-HSCR, L-HSCR, and TCA).3 The three features
signify two different types of effects: gender is a part of
the ‘‘genetic background’’ and can thus modify the muta-
tion effect whereas familiality and segment length are
outcomes probably modiﬁed by the mutation. We ﬁrst per-
formed the TDT across all 568 European, US, and Chinese
trios and 124 duos with complete data on all three
subtypes. The results in Table 2 imply three major conclu-
sions. First, rs2435357 has an effect on all forms and
subtypes of HSCR. Second, within each subtype there are
biological differences between classes. Thus, there are
moderate but nonsigniﬁcant differences in transmission
frequency by gender (p ¼ 0.13) but large signiﬁcant differ-
ences in transmission frequency by segment length (p ¼
7.6 3 105, ignoring unknown segment length) and fami-
liality (p ¼ 6.2 3 104). Third, estimation of the relative
allelic or genetic effect g shows that the mutational effect
is directly related to class frequency: the greater the
abundance of the class, the greater the genetic effect of
rs2435357. Thus, for the enhancer susceptibility allele,
the genetic effects are contrary to the Carter prediction
for all three features. Under mutation-selection balance,
the mutational effect on a phenotype is inversely propor-
tional to its frequency. Thus, the above results may be
a novel feature of multifactorial disease common variants.
To conﬁrm these ﬁndings, we directly estimated the
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Table 3. Prevalence of rs2435357 RET Genotypes by HSCR Subtypes
Chinese European
Genotype Male Female Male Female Short Long TCA Simplex Multiplex
CC 8 2 10 3 13 2 3 9 5
CT 17 6 22 6 32 4 5 20 7
TT 154 35 178 33 285 35 20 175 39
The prevalence (population penetrance) is shown as the number of cases per 100,000 live births, with both trios and case-control samples, with values in excess of
the background rate in bold. We assumed a population background rate of 15 cases and 28 cases per 100,000 live births in European ancestry and Chinese pop-
ulations, respectively. The Chinese samples were not used for segment length and familiality analyses because the overwhelming majority of samples were short
segment (173/192 cases) and simplex (190/192 cases).Chinese samples.9 We estimated the population proba-
bility of being affected given each genotype (population
penetrance or prevalence), by segment length, gender,
and familiality for the European ancestry sample, but
only by gender for the Chinese sample because there was
negligible variation in the other features (173 S-HSCR, 6
L-HSCR, 13 TCA; 190 simplex, 2 multiplex) (Table 3).
These results demonstrate three major features not evident
from Table 2. The estimated penetrance/prevalence values
are shown per 100,000 live births in comparison to the
population average of 15 per 100,000 European live births
and 28 per 100,000 Chinese live births. (Observed counts
of affecteds by these categories show signiﬁcant differences
in risk for all three risk factors in the European sample but
not for the Chinese sample where the sample size is smaller
[Table S5].) First, the estimated population penetrance/
prevalence values, within each category, vary by two orders
of magnitude with some genotypes elevating risk 20- to 40-
fold above the average. The greatest risk is for TT homozy-
gotes across all subclasses (male versus female, short versus
long versus TCA, multiplex versus simplex), but the only
elevated risks for CT heterozygotes are in the commonest
male/S-HSCR/simplex subclass. In other words, the effect
of rs2435357T is largely recessive but with some effect in
heterozygotes only in the most common categories.
Second, the penetrance or prevalence or risk, within each
disease subtype, is ampliﬁed 3- to 4-fold for the most
frequent class (male, S-HSCR, simplex) in the population.
This relationship is unexpected for Mendelian rare muta-
tions and has not been previously observed for a multifac-
torial phenotype. Third, although the data are limited,
penetrance of rs2435357T in the Chinese is similar to
that in the Europeans. Thus, the allele frequency of the
susceptibility allele is higher in the Chinese but the genetic
effect is near identical to that in the European sample.
Consequently, the HSCR prevalence difference in these
two populations is highly correlated with the allele fre-
quency or haplotype difference.
These results suggest that the rs2435357 genetic effect is
not constant but signiﬁcantly modiﬁable by gender and
other factors that regulate segment length and familiality
although additional, larger, and independent studies will
be needed to state this deﬁnitively. All of these subtypes
are themselves dependent on additional genes and devel-68 The American Journal of Human Genetics 87, 60–74, July 9, 2010opmental processes, so our result for HSCR is a clear
example of the quantitative effects of genetic background
on mutant allele/disease expression.
Rare Coding and Polymorphic RET Mutations Have
Complementary Effects in HSCR
More than 100 RET mutations, generally rare, missense
changes segregating with disease in families and absent
in unaffected controls,8 unlike the common enhancer
polymorphism,9 are known in familial and syndromic
HSCR patients. To study the contribution of all variants
across the allelic spectrum and for a diverse phenotypic
set of probands, we performed a comprehensive variation
(mutation) detection study. The distributions of these
probands according to whether they harbor a rare coding
(CDS) mutation only, the common enhancer variant (CT
or TT) only, neither, or both are presented in Figure 3.
The genotyping and sequencing was complete for 577
probands and, among these, the numbers were 73 (13%),
382 (66%), 45 (8%), and 77 (13%) cases with nomutations,
enhancer variant only, CDS variant only, and both disease
allelic types, respectively.
The frequency distributions of these four mutational
classes can be classiﬁed according to the three disease
subtypesweexaminedbefore (Table S6). Theﬁrstnoticeable
feature is that 13% (range: 9%–18%) of probands have no
identiﬁable RETmutation, with the general trend that total
mutation frequency is lower in the less common and more
heritable classes (females, TCA). Our mutation detection
protocols were comprehensive but we cannot ignore the
possibility of additional undetected RETmutations, partic-
ularly additional regulatory variants. In any case, the iden-
tiﬁable fraction of RET mutations is 87% and shows its
major genetic effect in HSCR. The RET-negative cases
may have mutations at other genes10 or could have HSCR
from environmental, stochastic, or epigenetic effects that
reduce RET function. The second feature of these data is
the preponderance of the enhancer mutation in all cate-
gories and its higher frequency in the commoner risk
classes (male, S-HSCR, simplex): the enhancer mutation is
directly proportional to the risk factor class frequency but
inversely proportional to its penetrance and thus recur-
rence risk. These analyses suggest that CDS and enhancer
RET mutations have quite distinct, complementary, and
Figure 3. Proportion of Patients with Rare and Common Muta-
tions Classified by Gender, Segment Length, and Familiality
Frequencies of RET coding sequence (CDS) and enhancer muta-
tion distribution in probands within HSCR subtypes. In each
case, the percent of patients with no identiﬁed mutation,
enhancer mutation only, CDS mutation only, and both enhancer
and CDSmutations are shown (plus andminus signs indicate pres-
ence/absence) together with the respective sample size in each
subgroup. A qualitative scale, demonstrating the direction of
increase (decrease) in recurrence risk (incidence) of the categories
from left to right, is shown.even opposite, genetic properties with regard to frequency,
genetic effect, recurrence risk, and frequency of a disease
subtype class. Indeed, the frequency of the rs2435357T
allele is 27%, 52%, 60%, and 66% among CDS mutation-
positive multiplex, CDS mutation-negative multiplex,
CDS mutation-positive simplex, and CDS mutation-nega-
tive simplex probands, respectively.Modeling of the haplo-
type frequencies of these two types of mutations, based on
the observation in cases estimates the frequencies of haplo-
types containing no mutations, enhancer mutation only,
CDS mutation only, and both mutations as 0.356, 0.532,
0.096, and 0.015, respectively. This suggests that almost
all enhancer alleles exist with CDS mutations in trans and
not cis. Moreover, the frequency of the enhancer variantThamong those without a CDS mutation is 0.532/(0.356 þ
0.532) ¼ 0.60 whereas the frequency among those with
aCDSmutation is 0.015/(0.096þ 0.015)¼ 0.14 and smaller
than the background frequency of 0.24. This negative asso-
ciation between the occurrence of coding mutations and
the enhancer variant is highly signiﬁcant (c21 ¼ 26.84,
p ¼ 2.2 3 107). This suggests that association studies of
RET would be much less powerful in multiplex (usually
CDS mutation-positive) as compared to simplex (CDS
mutation-negative) cases.
The mutation distribution in Figure 3 also shows that
only a minority of patients have RET CDSmutations alone.
Moreover, the frequency of those with both a cds and
the enhancer mutations is greater than those with a single
CDS mutation in six of the seven subclasses; they are
about equal in multiplex families where the enhancer
has no additional effect. Among all cases, the numbers of
probands who harbor the enhancer variant is 84% (382/
455) among those without a CDS mutation and 63% (77/
102) among those with a CDS mutation, a difference
that shows marginal signiﬁcance (p ¼ 0.04). Thus, the
enhancer mutation also exerts an effect in patients with
a coding mutation but the effect is attenuated relative to
the primary deleterious effect of a structural RETmutation.
This interaction between rare and common variants
within the same gene is analogous to that observed at
CFH (MIM 134370) in age-related macular degeneration
(MIM 610698)28 and suggests a recessive effect. Additional
types of mutations in RET undoubtedly exist. For example,
we have used the genotype data to search for trios in which
the failure of Mendelian segregation of RET SNPs is consis-
tent with de novo deletions. Figure 4 shows nine families
with evidence of deletions supported by multiple markers
and occurring in families with diverse phenotypes. Of
these, six cases arose in the maternal germline and one
in the paternal germline (two were indeterminate). These
data support the existence of deletions in a small fraction
(~1%) of all cases and are unlikely to compromise our inter-
pretations greatly.Discussion
Despite the great interest in complex disease genetics and
the success of genome-wide association studies (GWAS)
for gene mapping, we still have a meager understanding
of the speciﬁc genes, the allelic spectrum of susceptibility
variants, and the genetic mechanisms that underlie these
phenotypes.29 The basic inheritance model for complex
diseases is multifactorial inheritance,1,2 and the large
numbers of variants of small additive effects across alleles
and loci identiﬁed in GWAS supports this model. However,
this is a statistical model adequate for explaining some
features of inheritance, such as the contribution of speciﬁc
genes to heritability or the correlations between or recur-
rence risk to relatives, but not a molecular model of gene
action that is necessary for understanding the genetice American Journal of Human Genetics 87, 60–74, July 9, 2010 69
Figure 4. Mendelian Errors Compatible
with Gene Deletion
Nine affected individuals with patterns of
Mendelian inconsistencies suggestive of
deletion are shown (each row represents
a proband). RET exons (brown) and geno-
typed SNPs (blue) are shown across the
top, in scale. For each proband, the longest
RET region consistent with a deletion is
represented: SNPs that are Mendelian
inconsistent between parents and children
are shown in solid color; SNPs that are
Mendelian consistent but for which the
child is homozygous are stippled in color.
The entire genomic region is shown for
illustrative purposes but only the SNPs
were examined. Putative deletions occur-
ring in the maternal and paternal germ-
lines, or those with uncertain origin, are
colored in purple, orange, and green,
respectively. All deletions, but two, involve
multiple exons.properties of the component genes. HSCR, and the studies
described here, remains a compelling ‘‘model disease’’ for
elucidating the latter molecular properties and connecting
them to the former statistical properties.
In this study, we have replicated our prior discovery of
a common, noncoding enhancer mutation (rs2435357)
associated with HSCR in US samples to a larger European
sample, discovered a similar association in Chinese
samples, identiﬁed the molecular basis of the suscepti-
bility, identiﬁed interactions between numerous pheno-
typic subclasses and RET variants, and quantiﬁed the
relative contributions of rare and common RET variants
to HSCR. We have speciﬁcally demonstrated that (1) the
functional susceptibility at the RET enhancer MCSþ9.7
arises from the failure of SOX10 to activate RET transcrip-
tion; (2) the susceptibility T allele probably arose as a single
mutation after humans had left Africa and expanded in
both range and frequency toward Asia; (3) the European
(24%) and Chinese (47%) T allele frequency is signiﬁcantly
elevated in HSCR cases and sufﬁcient to explain the
prevalence difference between these two populations; (4)
rs2435357 is a genetic susceptibility factor in all pheno-
typic forms of HSCR but with quantitatively different
effects; (5) the penetrance of the T allele is higher in
individuals who have the more common subtypes (male,
S-HSCR, and simplex cases) with lower recurrence risk in
relatives, whereas coding sequence mutations are more
abundant in the less frequent subtypes (female, L-HSCR/
TCA, and multiplex cases) with higher recurrence risk in
relatives (this negative association is highly signiﬁcant at
p¼ 2.23 107) ; and (6) rs2435357 also has a genetic effect
in those harboring rare coding mutations. Additional RET
coding sequence polymorphisms exist,11 but assessing
their speciﬁc contribution, beyond their correlated effect
resulting from LD with rs2435357, will require functional
assays for each. Nevertheless, the existing features satisfy
many of the properties of the multifactorial model at
the phenotypic level (recurrence risk inversely related to70 The American Journal of Human Genetics 87, 60–74, July 9, 2010incidence, increased with greater clinical severity, and
greater from the less frequently affected class) for the rare
coding mutations but are violated by the common non-
coding variant at MCSþ9.7. Our analyses show that
different subclasses of the phenotype have different muta-
tional proﬁles and, once recognized, improve genotype-
phenotype correlations and enhance the proportion of
the risk that the RET gene explains. Nevertheless, there
must be additional variation unlinked to RET that also
impacts the observed differences in HSCR risk by gender,
familiality, and segment length.8,10
Genetic counseling for recurrence of multifactorial
diseases involve quoting a small, ﬁxed risk of 3% to all con-
sultands, but our RET results strongly suggest that both
phenotypic features and family history will need to be
accounted for. This is clearly possible for the total pheno-
type given family history, segment length, gender,4 rare
coding mutations (that are incompletely penetrant
dominant and recessives), and syndromic cases (based on
the molecular karyotype). Incorporating the effects of
common variants such as rs2435357 that have large rela-
tive risks is possible (Table 3) but will make little quantita-
tive change to the absolute risks we have published before4
because this is only one of several genes, each of small
effect. Consequently, one needs well-designed outcome
studies to assess how such risks may be understood by con-
sultands and how it might change their attitudes.
A second signiﬁcant ﬁnding from our analyses is the
‘‘inconstant and modiﬁable’’30 nature of the common
enhancer variant. Unlike Mendelian HSCR variants, the
enhancer variant does not have ﬁxed genetic effects on
HSCR but are contextual and depend on genetic and other
host factors and disease subtypes (gender, segment length,
familiality). We do not know the speciﬁc factors that lead
to these properties but they probably depend on both
random (environmental effects, stochastic factors) and
nonrandom (interaction effects through other genes, such
as those on chromosome 2131 or epigenetic modiﬁcation
Figure 5. Segregation of Both a Rare and Common Mutation in a HSCR Pedigree
A family segregating S-HSCR, L-HSCR, and TCAwith two RETmutations, a rare nonsense mutation (Y981X) and the common enhancer
variant (rs2435357), is shown with genotypes of relevant individuals only. The Y981X mutation is inherited by all affected individuals
from the paternal grandfather (I-I) and is present in two unaffected individuals (I-I and II-4). However, the severe forms of L-HSCR and
TCA in the grandchildren (III-I and III-3) also harbor the common enhancer variant inherited instead from the individualsmarrying into
this family (II-I and II-5). This represents a case of allelic penetrance modiﬁcation of a nonsense mutation.of RET) factors. Nevertheless, our study shows that which
patients we choose for a genetic study may strongly deter-
mine the types of genetic variants we uncover. Thus,
GWAS of multiplex cases biased with female, L-HSCR/TCA
patients may have low power for detecting common
variants whereas studies of simplex cases biased with
male, S-HSCR patients will have inadequate power for
detecting rare variants.9,32,33 These differences are usually
attributed to frequency of the disease variant but at its
basis are strongly affected by the phenotype subtypes we
choose to study. Thus, for molecular understanding of
a complex disease, a broad gamut of phenotypes covering
familial and isolated cases needs to be examined to
assess the complete contributions of genes and variants to
heritability.
The debate on the frequency of disease alleles in
common disorders often treats common and rare alleles
as two distinct classes. However, disease outcome and
penetrance depends on the genotype and can include
both types of alleles. Consider the HSCR pedigree shown
in Figure 5 that segregates HSCR in an incompletely pene-
trant autosomal-dominant manner with variable expres-
sivity (II-2 has S-HSCR, III-1 has L-HSCR, and III-3 has
TCA) but, at the sequence level, has been demonstrated
to segregate both a rare nonsense mutation (Y981X)
and the enhancer susceptibility allele at rs2435357. The
severely affected individuals harbor both mutations
whereas carriers of Y981X only are either mildly affected
(II-2) or unaffected (I-1, II-4). Here, rs2435357T (inherited
from the two males who married into the family, II-1 and
II-5) modiﬁes the penetrance of the Y981X allele in trans
(interallelic interaction) and suggests that rs2435357T in
cis should have no additional effect on the null allele.
This hypothesis needs to be tested in a larger sample ofThcases with cis- versus trans-haplotypes harboring a coding
mutation. These data also suggest that the RET genetic
effect in the severe cases is more recessive than dominant
and is the likely cause of the small but perceptible effect
of rs2435357 in patients with rare coding mutations.
The two classes of RET mutations affect distinct genetic
aspects of RET: rare changes that reduce RET signaling
(loss of function in any of the several functional domains
within RET) and a common variant that reduces RET tran-
scription. The former variants produce a mutant protein
with compromised function whereas the latter variant
produces reduced amounts of a wild-type protein. Speciﬁ-
cally, how these two different biological alterations, some-
times in the same patient (Figure 5), lead to HSCR is
unknown. Given that the majority of susceptibility alleles
mapped by GWAS appear to be similar to the rs2435357
rather than the coding variants, it is possible that their
genetic properties may be different from those we have
classically come to expect from studies of rare Mendelian
phenotypes. The complementary genetic effects of these
two types of mutations is a key ﬁnding of our studies
and, hopefully, is a model for other complex diseases
because it is known in other cases such as LDLR (MIM
606945) variants and LDL cholesterol. In other words,
many diseases may be disorders of protein quantity rather
than quality.34,35
Despite the ﬁndings of this study and their implications,
we require additional independent replications of these
ﬁndings. Such new studies could take additional notice
of randomizing patient ascertainment, particularly with
respect to subtypes and improved diagnosis utilizing clin-
ical-radiological-pathological data and from additional
populations. In addition, higher-resolution genetic anal-
ysis of RET together with marker data across the genomee American Journal of Human Genetics 87, 60–74, July 9, 2010 71
could add greater support to the results. With multiple
common and rare variants, we could start to address how
molecular genotypes can modify the recurrence risk in
individual cases.
Recent HSCR studies provide some new insights into the
genetic mechanisms involved. The early discovery of RET
deletions in HSCR patients36 suggested that RET haploin-
sufﬁciency was the genetic cause of HSCR; however, in
the mouse, RET null mutations37 do not display aganglio-
nosis except in homozygotes, suggesting complete loss of
function as the primary cause. Although originally recon-
ciled as human-mouse developmental differences, four
types of information now suggest that these are not real
differences: (1) we have previously shown that compound
Ret null heterozygote-Ednrb hypomorphic homozygote
genotypes in the mouse display full penetrance and
phenotypic features similar to humans (variation in
segment length and sex ratio alteration);38 (2) all RET
mutations in HSCR, be they in the coding sequence
leading to a mutant protein39 that fails to appropriately
transduce the signal from its ligand GDNF or from reduced
transcriptional activity of RET affected through the
binding of SOX10 at the MCSþ9.7 enhancer,15,40 are
partial or complete genetic loss-of-function mutations;
(3) the effects of the rs2435357T enhancer mutation is
5- to 10-fold greater in TT homozygotes than CT heterozy-
gotes and the enhancer mutation is at elevated frequency
even in cases with a coding mutation; and (4) interacting
proteins, such as overexpressed SOD1, can reduce RET
dimerization41 and consequent loss of function. These
results jointly suggest that HSCR may result only when
>50% of RET function has been lost irrespective of
whether this loss arises from structural or regulatory muta-
tions within the gene or from interactions with other
susceptibility genes.8,31 The studies presented here show
that 87% of the RET alleles in patients have mutations,
which is more than what a heterozygote effect demands
and close to recessive genetic action. We suspect, but
cannot yet prove, that the remaining 13% also harbor
alleles with compromised function whether they are
compromised by the actions of interacting genes or epige-
netic markings or random environmental factors. In other
words, RET mutations may be necessary for HSCR patho-
genesis so that RET is a rate-limiting step in enteric
ganglion cell development.
We hypothesize that HSCR is a cellular recessive,
analogous (but not genetically identical) to the childhood
cancer retinoblastoma,42 and requires two ‘‘hits’’ to RET.
There are many similarities in patterns between these
two disorders with respect to transmission (familiality
versus laterality), expressivity and severity (segment length
versus number of tumor foci), and inheritance (syndromic/
isolated cases and Mendelian versus complex inheritance).
Such a model can also potentially account for why the
penetrance of mutations is not complete and why
additional genes may be required. For retinoblastoma,
additional mutations, all somatically acquired, select for72 The American Journal of Human Genetics 87, 60–74, July 9, 2010growth of the tumor whereas in HSCR, additional muta-
tions (genetic evidence suggesting that many of these are
inherited) are those that fail to rescue the early RET loss
of function. We can begin to appreciate why individuals
with the wild-type genotypes at RET can be affected with
HSCR. Some of these could simply be the effect of other
genes or could arise from nonheritable variation. Cell
biology and modeling studies have shown the crucial
importance of genetic control of precursor neural crest
cell number during development.43 We believe that per-
turbing this cell number, by any mechanism, is essential
to HSCR and a major explanation of the variation in pene-
trance by RETmutations. Thus, a search for mutations that
control precursor neural crest cell number may be key to
understanding HSCR.Supplemental Data
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